Standard

Identification of MHC class II restricted T‐cell‐mediated reactivity against MHC class I binding Mycobacterium tuberculosis peptides. / Wang, Mingjun; Tang, Sheila Tuyet; Stryhn, Anette; Justesen, Sune; Larsen, Mette Voldby; Dziegiel, Morten H.; Lewinsohn, David M.; Buus, Søren; Lund, Ole; Claesson, Mogens H.

In: Immunology, Vol. 132, No. 4, 2011, p. 482-491.

Publication: Research - peer-reviewJournal article – Annual report year: 2011

Harvard

APA

CBE

MLA

Vancouver

Author

Wang, Mingjun; Tang, Sheila Tuyet; Stryhn, Anette; Justesen, Sune; Larsen, Mette Voldby; Dziegiel, Morten H.; Lewinsohn, David M.; Buus, Søren; Lund, Ole; Claesson, Mogens H. / Identification of MHC class II restricted T‐cell‐mediated reactivity against MHC class I binding Mycobacterium tuberculosis peptides.

In: Immunology, Vol. 132, No. 4, 2011, p. 482-491.

Publication: Research - peer-reviewJournal article – Annual report year: 2011

Bibtex

@article{e609cfac88ab4e0d9ee66f388d6f0b01,
title = "Identification of MHC class II restricted T‐cell‐mediated reactivity against MHC class I binding Mycobacterium tuberculosis peptides",
keywords = "HLA-I, HLA-II, Mycobacterium tuberculosis; vaccine, Cytotoxic T lymphocyte epitope",
publisher = "Wiley-Blackwell Publishing Ltd.",
author = "Mingjun Wang and Tang, {Sheila Tuyet} and Anette Stryhn and Sune Justesen and Larsen, {Mette Voldby} and Dziegiel, {Morten H.} and Lewinsohn, {David M.} and Søren Buus and Ole Lund and Claesson, {Mogens H.}",
year = "2011",
doi = "10.1111/j.1365-2567.2010.03383.x",
volume = "132",
number = "4",
pages = "482--491",
journal = "Immunology",
issn = "0019-2805",

}

RIS

TY - JOUR

T1 - Identification of MHC class II restricted T‐cell‐mediated reactivity against MHC class I binding Mycobacterium tuberculosis peptides

A1 - Wang,Mingjun

A1 - Tang,Sheila Tuyet

A1 - Stryhn,Anette

A1 - Justesen,Sune

A1 - Larsen,Mette Voldby

A1 - Dziegiel,Morten H.

A1 - Lewinsohn,David M.

A1 - Buus,Søren

A1 - Lund,Ole

A1 - Claesson,Mogens H.

AU - Wang,Mingjun

AU - Tang,Sheila Tuyet

AU - Stryhn,Anette

AU - Justesen,Sune

AU - Larsen,Mette Voldby

AU - Dziegiel,Morten H.

AU - Lewinsohn,David M.

AU - Buus,Søren

AU - Lund,Ole

AU - Claesson,Mogens H.

PB - Wiley-Blackwell Publishing Ltd.

PY - 2011

Y1 - 2011

N2 - Major histocompatibility complex (MHC) class I restricted cytotoxic T lymphocytes (CTL) are known to play an important role in the control of Mycobacterium tuberculosis infection so identification of CTL epitopes from M. tuberculosis is of importance for the development of effective peptide‐based vaccines. In the present work, bioinformatics technology was employed to predict binding motifs of 9mer peptides derived from M. tuberculosis for the 12 HLA‐I supertypes. Subsequently, the predicted peptides were synthesized and assayed for binding to HLA‐I molecules in a biochemically based system. The antigenicity of a total of 157 peptides with measured affinity for HLA‐I molecules of KD ≤ 500 nm were evaluated using peripheral blood T cells from strongly purified protein derivative reactive healthy donors. Of the 157 peptides, eight peptides (5%) were found to induce T‐cell responses. As judged from blocking with HLA class I and II subtype antibodies in the ELISPOT assay culture, none of the eight antigenic peptides induced HLA class I restricted CD8+ T‐cell responses. Instead all responses were blocked by pan‐HLA class II and anti‐HLA‐DR antibodies. In addition, CD4+ T‐cell depletion before the 10 days of expansion, resulted in total loss of reactivity in the ELISPOT culture for most peptide specificities. FACS analyses with intracellular interferon‐γ staining of T cells expanded in the presence of M. tuberculosis peptides confirmed that the responsive cells were indeed CD4+. In conclusion, T‐cell immunity against HLA‐I binding 9mer M. tuberculosis‐derived peptides might in many cases turn out to be mediated by CD4+ T cells and restricted by HLA‐II molecules. The use of 9mer peptides recognized by both CD8+ and CD4+ T cells might be of importance for the development of future M. tuberculosis peptide‐based vaccines.

AB - Major histocompatibility complex (MHC) class I restricted cytotoxic T lymphocytes (CTL) are known to play an important role in the control of Mycobacterium tuberculosis infection so identification of CTL epitopes from M. tuberculosis is of importance for the development of effective peptide‐based vaccines. In the present work, bioinformatics technology was employed to predict binding motifs of 9mer peptides derived from M. tuberculosis for the 12 HLA‐I supertypes. Subsequently, the predicted peptides were synthesized and assayed for binding to HLA‐I molecules in a biochemically based system. The antigenicity of a total of 157 peptides with measured affinity for HLA‐I molecules of KD ≤ 500 nm were evaluated using peripheral blood T cells from strongly purified protein derivative reactive healthy donors. Of the 157 peptides, eight peptides (5%) were found to induce T‐cell responses. As judged from blocking with HLA class I and II subtype antibodies in the ELISPOT assay culture, none of the eight antigenic peptides induced HLA class I restricted CD8+ T‐cell responses. Instead all responses were blocked by pan‐HLA class II and anti‐HLA‐DR antibodies. In addition, CD4+ T‐cell depletion before the 10 days of expansion, resulted in total loss of reactivity in the ELISPOT culture for most peptide specificities. FACS analyses with intracellular interferon‐γ staining of T cells expanded in the presence of M. tuberculosis peptides confirmed that the responsive cells were indeed CD4+. In conclusion, T‐cell immunity against HLA‐I binding 9mer M. tuberculosis‐derived peptides might in many cases turn out to be mediated by CD4+ T cells and restricted by HLA‐II molecules. The use of 9mer peptides recognized by both CD8+ and CD4+ T cells might be of importance for the development of future M. tuberculosis peptide‐based vaccines.

KW - HLA-I

KW - HLA-II

KW - Mycobacterium tuberculosis; vaccine

KW - Cytotoxic T lymphocyte epitope

U2 - 10.1111/j.1365-2567.2010.03383.x

DO - 10.1111/j.1365-2567.2010.03383.x

JO - Immunology

JF - Immunology

SN - 0019-2805

IS - 4

VL - 132

SP - 482

EP - 491

ER -